Eddie Pharmaceuticals today the company's board listed, anti-AIDS new drugs are expected to be reported by the end of the year.

On July 20, Jiangsu Eddy Pharmaceutical Co., Ltd("Eddie Pharmaceuticals") was officially listed on the company's board, with no more than 90 million shares issued and an issue price of 13.99 yuan per share, corresponding to a price-earnings ratio of 285.07 timesAccording to the prospectus disclosure, Eddy Pharmaceuticals this company's listing to raise 746 million yuan, will be used for innovative drug research and development, the purchase of research and development technology center building, raw materials production research and development and supporting facilities construction, as well as repayment of bank loans, supplementary working capitalAmong them, the acquisition project of the Research and Development Technology Center Building is to be implemented by Anselais, and the research and development of API production and supporting facilities is implemented by Eddy Pharma, a wholly owned subsidiary of Eddy PharmaceuticalsWhen the funds are raised, Eddy Pharmaceuticals will raise funds to increase capital or borrow money into Athens and Eddy Pharmaceuticals, and other projects will be implemented by itselfEddy Pharmaceuticals adopted the second set of listing criteria in the IPO of Cotron Board, that is, "the expected market value is not less than RMB1.5 billion, the last year's operating income is not less than RMB200 million, and the cumulative research and development investment in the last 3 years accounted for the proportion of cumulative operating income in the last 3 years is not less than 15%." 」。 According to the prospectus, The last external equity financing of Aedi Pharmaceuticals, in which institutional investors raised capital in 2017, was valued at 1.6 billion yuanFrom 2017 to 2019, Eddie Pharmaceuticals' operating income was RMB136 million, RMB277 million and RMB345 million, respectivelyDuring the same period, the research and development expenses were RMB42.1435 million, RMB61,876.4 million and RMB56.9634 million, respectively, and the cumulative investment in research and development in the past three years accounted for 21.23% of the cumulative operating income in the past three years, which met the listing criteriaAccording to the prospectus, the controlling shareholder of Eddy Pharmaceuticals is Guangzhou Weimei Investment Co., Ltd., the actual controller is Fu Heliang, Jindi Wu and his wifeFu and Liang, chairman, general manager and chief executive officer of the company, own simply 26.25% of Eddie Pharmaceuticals voting rights through Guangzhou Vime, and Jindi Wu, Fu and Liang's wife, own 26.08% of Eddie Pharmaceuticals through Hong Kong's Vime and AEGEL TECHFu and Jindi Wu together have 52.33 percent of The voting rights of Eddy PharmaceuticalsEddie Pharmaceuticals equity structure map human source protein products contribute more than 70% of revenue Eddy Pharmaceuticals was established in 2009, is a human-derived protein products production, sales-based biological products enterprises, while carrying out part of the generic sorority business and distribution of Abbott's HIV diagnostic reagents and equipment businessAmong them, in 2017-2019, the company's source protein products operating income reached 112 million yuan, 218 million yuan and 260 million yuan, respectively, accounting for 82.27 percent, 78.65 percent and 75.19 percent of the company's operating income in the same period, is the company's main source of profitIt is worth noting that Eddie Pharmaceuticals' sales revenue from human-derived protein products is currently more dependent on the largest customer, TempbioFrom 2016 to June 2019, The sales of Tempu Biochemicals amounted to RMB 234 million, RMB069 million, RMB191 million and RMB098 million, respectively, accounting for 90.79 percent, 50.64 percent, 69.11 percent and 60.46 percent of The company's revenue for the same periodIn this regard, Eddy Pharmaceuticals explained in the prospectus that injection of ustadine and injection of Uriklin is the exclusive variety of Tempbio, and Eddy Pharmaceuticals is currently the only supplier that can provide Ustadine crude and Juriclin crude to The Tempu Biochemical Scale, so the two sides reached a long-term industrial relationshipHowever, in the event of a major adverse change in the industrial partnership between Tampon Andi Pharmaceuticals, or fluctuations in Theoperating Status of Tempu Biochemicals, it is likely to have a significant adverse impact on the operating performance of Eddy PharmaceuticalsNew anti-AIDS drugs are expected to be reported by the end of 2014, Eddy Pharmaceuticals began to transform the layout of innovative drug research and development, aiming at AIDS, inflammation and malignant tumors and other major diseasesUp to now, Eddy Pharmaceuticals' research and development pipeline covers 12 mainly in the research varieties, including 6 core 1 new drugs, 1 class 2 new drugs, 3 generic drugs, and 2 categories of declaration consistency evaluationEddy Pharmaceuticals' fastest clinically advanced project in the research product pipeline is the new anti-AIDS drug ACC007, a new generation of non-nucleoside reverse transcriptase inhibitors that block viral transcription and replication through non-competitive binding and inhibiting HIV reverse transcriptase activityThe drug has now completed Phase III clinical trials and is expected to be listed this yearACC008 is another of Aedi Pharmaceuticals in the field of anti-AIDS research class 1 new drug, for fixed doses of three-way monosheet compound preparations, each containing ACC007, tenofovir and Ramifding 3 main ingredientsCompared with single medicine, single-chip compound preparation can significantly reduce the burden of taking drugs, increase compliance and reduce the occurrence of drug resistanceIn October 2019, CDE initially agreed that bioequivalence trials could be used for primary treatment of patients and that Phase III clinical trials could be conducted for patientsIn the field of anti-tumor, Eddy Pharmaceuticals also has a product layoutACC006 is a new type of dual-target anti-tumor drug acting on the mTOR pathway and the Hedgehog pathway, selectively inhibiting tumor cell proliferation and inducing tumor cell apoptosisAt present, the drug for advanced styloid cell carcinoma Phase II clinical trialist is actively in communication with relevant parties on clinical solutions, the future is expected to be "orphan medicine" as the market approvalAt the same time, Eddy Pharmaceuticals is conducting a clinical trial of IB/II for the treatment of lung scale cancer in the ACC006 Joint Standard First Line Chemotherapy ProgramACC010 is a bromine domain protein 4 (BRD4) inhibitor used to treat patients with acute myeloid leukemiaAt present, the drug has been clinical approval of the new drug, is carrying out Phase I clinical trial preparationsACC015 is a new type of nucleoside anti-tumor drug, mainly used for the treatment of acute leukemia patients, is still in the preclinical research stage